<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2612">
  <stage>Registered</stage>
  <submitdate>11/12/2009</submitdate>
  <approvaldate>11/12/2009</approvaldate>
  <nctid>NCT01031199</nctid>
  <trial_identification>
    <studytitle>Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers</studytitle>
    <scientifictitle>Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2008-000981-22</secondaryid>
    <secondaryid>13101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Positron-Emission Tomography</healthcondition>
    <healthcondition>Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - F-18 FEDAA1106 (BAY85-8101)
Treatment: drugs - F-18 FEDAA1106 (BAY85-8101)

Experimental: Arm 1 - 

Experimental: Arm 2 - 


Treatment: drugs: F-18 FEDAA1106 (BAY85-8101)
MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer &lt; 5 µg, PET

Treatment: drugs: F-18 FEDAA1106 (BAY85-8101)
Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer &lt; 5 µg, PET

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Standard quantification variables derived from 3D PET imaging and brain modeling.</outcome>
      <timepoint>Day of study tracer administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Visual analysis/description of the uptake and description of brain PET scans.</outcome>
      <timepoint>Day of study tracer administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Standard Safety Parameter: Adverse Event Collection</outcome>
      <timepoint>maximum time from Screening to Follow-up are 37days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard Safety Parameter: Electrocardiogram</outcome>
      <timepoint>maximum time from Screening to Follow-up are 37days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard Safety Parameter: Safety laboratory</outcome>
      <timepoint>maximum time from Screening to Follow-up are 37days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard Safety Parameter: Vital signs</outcome>
      <timepoint>maximum time from Screening to Follow-up are 37days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers for brain imaging:

          -  males or females, age 20 - 55 years

          -  assessment of the brain MRI as "normal (age-appropriate)"

          -  absence of any sign of CNS disease, no co-medi cation Patients for brain imaging

          -  males or females, age 20 - 55 years

          -  patients with previously diagnosed MS, presenting with acute relapse, without any
             current immunomodulating therapy for MS ("drug-naïve"), or patients presenting with
             first clinical episode suggestive of demyelinating disease (Clinically Isolated
             Syndrome, CIS)

          -  patients with previously diagnosed MS, presenting with acute relapse, receiving
             currently immunomodulatory therapy exclusively with interferon ß

          -  MRI: &gt;/= 2 T2 lesions and &gt;/= 1 Gadolinium- (Gd-) enhancing lesion</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria for all healthy volunteers and patients:

          -  Pregnancy or lactation

          -  Any disease, condition, or concomitant medications that significantly compromises the
             function of the body systems and could result in excessive accumulation, impaired
             metabolism, altered excretion of the radiotracer, or might interfere with the conduct
             of the study or interpretation of the results

          -  other forms of diseases with neuroinflammatory components</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Heidelberg</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with
      Multiple Sclerosis compared to healthy volunteers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01031199</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>